Oruka Therapeutics (NASDAQ:ORKA) SVP Arjun Agarwal Sells 10,290 Shares

by · The Cerbat Gem

Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) SVP Arjun Agarwal sold 10,290 shares of the firm’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $59.07, for a total value of $607,830.30. Following the transaction, the senior vice president owned 16,406 shares in the company, valued at approximately $969,102.42. This trade represents a 38.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arjun Agarwal also recently made the following trade(s):

  • On Monday, March 16th, Arjun Agarwal sold 395 shares of Oruka Therapeutics stock. The shares were sold at an average price of $41.30, for a total value of $16,313.50.

Oruka Therapeutics Price Performance

Shares of Oruka Therapeutics stock traded down $3.59 during trading hours on Monday, hitting $58.34. 1,905,934 shares of the company’s stock traded hands, compared to its average volume of 1,049,294. Oruka Therapeutics, Inc. has a 12-month low of $9.54 and a 12-month high of $91.00. The stock has a market capitalization of $3.52 billion, a price-to-earnings ratio of -30.07 and a beta of -0.20. The company has a fifty day simple moving average of $55.17 and a 200-day simple moving average of $39.42.

Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) last announced its earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.04. On average, analysts forecast that Oruka Therapeutics, Inc. will post -2.15 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on ORKA shares. Barclays raised their target price on Oruka Therapeutics from $78.00 to $160.00 and gave the company an “overweight” rating in a research report on Monday, April 27th. HC Wainwright reaffirmed a “buy” rating and set a $120.00 target price on shares of Oruka Therapeutics in a research report on Monday. Stifel Nicolaus lifted their price objective on Oruka Therapeutics from $47.00 to $72.00 and gave the stock a “buy” rating in a report on Friday, March 13th. Leerink Partners set a $120.00 price objective on Oruka Therapeutics in a report on Thursday, April 30th. Finally, BTIG Research reissued a “buy” rating and issued a $151.00 price objective on shares of Oruka Therapeutics in a report on Thursday. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $120.80.

View Our Latest Analysis on Oruka Therapeutics

Institutional Investors Weigh In On Oruka Therapeutics

Several large investors have recently added to or reduced their stakes in ORKA. Viking Global Investors LP purchased a new stake in Oruka Therapeutics in the 3rd quarter worth about $51,280,000. Paradigm Biocapital Advisors LP purchased a new stake in Oruka Therapeutics in the 4th quarter worth about $51,840,000. Remedium Capital Partners LLC purchased a new stake in Oruka Therapeutics in the 4th quarter worth about $47,054,000. Avoro Capital Advisors LLC purchased a new stake in Oruka Therapeutics in the 3rd quarter worth about $25,640,000. Finally, Deep Track Capital LP grew its holdings in Oruka Therapeutics by 38.4% during the 3rd quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock valued at $51,051,000 after buying an additional 735,983 shares in the last quarter. Hedge funds and other institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

(Get Free Report)

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.

Featured Articles